Notably, reversion mutations in BRCA2 mediating PARPi resistance have been reported in ovarian, breast, pancreatic and prostate cancer, highlighting the benefit of implementing molecular profiling to pre‐emptively detect them in clinical settings. The gene discussed is BRCA2; the disease is prostate cancer.